title: Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.
abstract: We have investigated the efficacy of mitoxantrone in combination with etoposide in patients with refractory acute myelogenous leukemia. The regimen consisted of 10 mg/m2/day of mitoxantrone given iv on Days 1-5; and 100 mg/m2/day of etoposide as short infusion, initially on Days 1-3 and extended to Days 4 and 5 as appropriate. Of the 26 patients treated with this combination, nine (34.6%) have achieved complete remission and two have achieved partial remission. The median duration of continuous complete remission was 85 days (range, 21-183+). Toxicity was mild and only one case of early death was observed. This combination seems to be an active regimen in refractory acute myelogenous leukemia, and its incorporation in front-line therapy seems warranted.
authors.forename: A D
authors.initials: AD
authors.lastname: Ho
authors.forename: T
authors.initials: T
authors.lastname: Lipp
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: P
authors.initials: P
authors.lastname: Meyer
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: W
authors.initials: W
authors.lastname: Hunstein
mesh_terms: D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone
chemical_list: D000880:Anthraquinones; D005047:Etoposide; D008942:Mitoxantrone